XINT.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:32):

Stats
今日成交量	203 502
平均成交量	242 698
市值	159.33M
EPS	SEK-0.0265 ( 2023-09-30 )
下一个收益日期	( SEK0 ) 2024-05-08
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.16
ATR14	SEK0.00500 (1.78%)

Xintela AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Xintela AB (publ) 财务报表

Annual	2023
营收:	SEK78 000.00
毛利润:	SEK-3.69M (-4 728.21 %)
EPS:	SEK-0.130

FY	2023
营收:	SEK78 000.00
毛利润:	SEK-3.69M (-4 728.21 %)
EPS:	SEK-0.130

FY	2022
营收:	SEK0
毛利润:	SEK-3.79M (0.00 %)
EPS:	SEK-0.370

FY	2021
营收:	SEK0.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-0.557

Financial Reports:

No articles found.

Xintela AB (publ)

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.